Biomedical subjects

P De Raadt

Publications and source records attributed to P De Raadt.

10 recordsLinked to original sources

PubMed1995

The 1901 uganda sleeping sickness epidemic revisited: a case of mistaken identity?

The great sleeping sickness epidemic that occurred in Busoga at the turn of the century was caused by a trypanosome identified by Bruce as Trypanosoma gambiense. A study of trypanosomes from the recent epidemic in southeast Uganda has shed new light on the origins of the disease in Busoga. Thorsten Koerner, Peter de Raadt and Ian Maudlin suggest that the epidemic of the turn of the century was of T. p. rhodesiense sleeping sickness, brought about then, as now by social upheaval.

Journal Article↗

PubMed1993

The burden of tropical diseases.

More than half the world's population is at risk of the tropical diseases malaria, leprosy, schistosomiasis, lymphatic filariasis, onchocerciasis, Chagas disease, African trypanosomiasis and leishmaniasis, and half a billion people are infected with at least one of these diseases. We present statistic on the population at risk and the infected population, and on the major morbidity and mortality attributable to each of these diseases. During the next decade the prevalence of leprosy, Chagas disease, and onchocerciasis is expected to fall, but for the other tropical diseases the epidemiological situation may remain stagnant or even worsen.

Global Health↗

PubMed1987

Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.

alpha-Difluoromethylornithine (DFMO; eflornithine), an inhibitor of polyamine biosynthesis, was used to treat 14 patients with late stage gambiense sleeping sickness, 12 cases having been previously treated with and considered refractory to melarsoprol. alpha-Difluoromethylornithine was administered intravenously at a dose of 400 mg/kg/day for 14 days followed by oral treatment, 300 mg/kg/day, for 21-28 days. In all patients treatment was associated with rapid disappearance of trypanosomes from body fluids (in several cases within 24 hr) and decreased cerebrospinal fluid white blood cell counts. In all but one patient, who died of a pulmonary infection during treatment, alpha-difluoromethylornithine produced a dramatic reversal of clinical signs and symptoms of the disease. Determination of drug concentrations in serum and cerebrospinal fluid of 5 patients demonstrated that alpha-difluoromethylornithine diffuses into the central nervous system with cerebrospinal fluid levels representing up to 51% of corresponding serum concentrations. Diarrhea, abdominal pain, and anemia were the most frequent side effects associated with therapy, but were reversible and did not necessitate discontinuation of treatment. Four patients have been followed for more than 2 years post-treatment without evidence of relapse.

Administration, Oral↗

PubMed1985

[Congenital trypanosomiasis and leishmaniasis].

Trypanosomas and leishmanias can cross the placenta. Trypanosoma cruzi (American trypanosomiasis or Chagas' disease) may infect the placenta, with or without fetal transmission (congenital trypanosomiasis). Congenital transmission of Chagas' disease is a real problem of public health. Risk of congenital infections is less important for African trypanosomiasis and leishmaniasis. However, physicians should always think of this diagnosis in individual cases, since these diseases may occur in any part of the world, including outside the endemic areas.

Chagas Disease↗

PubMed1978